Advancing Achondroplasia Care with Next-Generation CNP Therapy

Advances in targeted therapies are transforming the treatment landscape for rare genetic disorders, with a growing focus on improving both clinical outcomes and patient quality of life. Achondroplasia, the most common form of dwarfism, has historically had limited therapeutic options, but innovations in C-type natriuretic peptide (CNP)–based treatments are beginning to reshape care paradigms.

In this interview with MedTech Spectrum, Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children’s Hospital, discusses the clinical significance of YUVIWEL, a next-generation, once-weekly therapy designed to provide continuous CNP exposure. He shares insights into the therapy’s efficacy, safety profile, and potential to go beyond linear growth, highlighting how reduced treatment burden and improved adherence could meaningfully impact patients and caregivers alike.

How does YUVIWEL’s once-weekly design and continuous CNP exposure differentiate it clinically from previous approaches, and what does this mean for skeletal development and outcomes?

YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body.  Furthermore, YUVIWEL has a long half-life of over five days, providing continuous systemic exposure to CNP over the weekly dosing interval.  Other approved treatments for achondroplasia consist of a daily injection of a CNP analogue.

What key efficacy and safety findings from the pivotal trials supported FDA approval, particularly in terms of annualised growth velocity and overall tolerability?

In the pivotal 52-week trial of navepegritide (YUVIWEL), 84 children with achondroplasia (ages 2–11) were randomised 2:1 to YUVIWEL or placebo. As reported in JAMA Pediatrics, YUVIWEL increased annualised growth velocity by 1.49 cm compared to expected growth for achondroplasia. The treatment was well tolerated, with no clinically significant side effects, no symptomatic hypotension, and minimal injection site reactions.

Beyond linear growth, is there evidence or ongoing research on how sustained CNP exposure may impact broader complications associated with achondroplasia?

In the pivot trial, additional benefits beyond growth included improved skeletal alignment and body proportionality, as well as positive changes in health-related quality of life. Patients who received the treatment showed an improvement in the tibial-femoral angle. In addition, there was also an improvement in fibula to tibia length ratio and mechanical axial deviation; all of these are proxy measurements for leg alignment.

From a patient and caregiver perspective, how meaningful is the shift to a once-weekly treatment model in day-to-day life?

Weekly dosing of  YUVIWEL will help prevent injection fatigue that typically results from prolonged drug use and daily injections. Weekly injections will likely improve adherence, decrease injection-site discomfort and needle phobia, and reduce the burden that is typically associated with chronic use and disease burden perception. In the pediatric population, caretakers must handle the injections, which create further stress and demands in their schedule. A once-weekly regimen may help ease this burden and support improved quality of life.